Impaired polyfunctionality of CD8+ T cells in severe sepsis patients with human cytomegalovirus reactivation
- PMID: 28960213
- PMCID: PMC5628278
- DOI: 10.1038/emm.2017.146
Impaired polyfunctionality of CD8+ T cells in severe sepsis patients with human cytomegalovirus reactivation
Abstract
Human cytomegalovirus (HCMV) establishes a lifelong chronic latent infection and often reactivates in immunocompromised patients. In addition, HCMV reactivates in patients with sepsis or other critical illnesses, particularly in patients with poor prognoses. However, the immunological characteristics of sepsis patients with HCMV reactivation have not been elucidated. In the present study, we examined T-cell responses in severe sepsis patients with and without HCMV reactivation. First, HCMV pp65-specific T-cell functions were assessed by intracellular cytokine staining (ICS) for IFN-γ, TNF-α, and MIP-1β and by CD107a staining. We analyzed the ICS data for each function individually and found no difference between the patient groups. However, the relative frequency of polyfunctional CD8+ T cells was significantly decreased in sepsis patients with HCMV reactivation. Next, we examined programmed cell death protein 1 (PD-1) expression. It was significantly increased in the CD8+ T-cell population in severe sepsis patients with HCMV reactivation, indicating CD8+ T-cell exhaustion. Interestingly, the frequency of PD-1+ cells in the CD8+ T-cell population was inversely correlated with the relative frequency of polyfunctional CD8+ T cells. Herein, we demonstrate that HCMV reactivation in severe sepsis patients is associated with PD-1 expression and impaired polyfunctionality of CD8+ T cells.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Similar articles
-
Pre-transplant IE1-specific T-cell response and CD8+ T-cell count as predictive markers of treated HCMV reactivation in kidney transplant recipients.Front Immunol. 2025 Apr 16;16:1538795. doi: 10.3389/fimmu.2025.1538795. eCollection 2025. Front Immunol. 2025. PMID: 40308605 Free PMC article.
-
Phenotypic and Functional Differences between Human Herpesvirus 6- and Human Cytomegalovirus-Specific T Cells.J Virol. 2019 Jun 14;93(13):e02321-18. doi: 10.1128/JVI.02321-18. Print 2019 Jul 1. J Virol. 2019. PMID: 30996090 Free PMC article.
-
Human cytomegalovirus specific CD8(+) T lymphocytes display interferon-gamma secretion impairment in kidney transplant recipients with pp65 antigenemia.Transplant Proc. 2008 Dec;40(10):3500-4. doi: 10.1016/j.transproceed.2008.03.176. Transplant Proc. 2008. PMID: 19100424
-
Molecular characterization of HCMV-specific immune responses: Parallels between CD8(+) T cells, CD4(+) T cells, and NK cells.Eur J Immunol. 2015 Sep;45(9):2433-45. doi: 10.1002/eji.201545495. Epub 2015 Aug 24. Eur J Immunol. 2015. PMID: 26228786 Review.
-
Human cytomegalovirus infection and the immune response to exercise.Exerc Immunol Rev. 2016;22:8-27. Exerc Immunol Rev. 2016. PMID: 26853134 Review.
Cited by
-
Exosomes Derived From T Regulatory Cells Suppress CD8+ Cytotoxic T Lymphocyte Proliferation and Prolong Liver Allograft Survival.Med Sci Monit. 2019 Jul 1;25:4877-4884. doi: 10.12659/MSM.917058. Med Sci Monit. 2019. PMID: 31258152 Free PMC article.
-
The importance of a sepsis layered early warning system for critical patients.Am J Transl Res. 2022 Aug 15;14(8):5229-5242. eCollection 2022. Am J Transl Res. 2022. PMID: 36105025 Free PMC article. Review.
-
Surviving Sepsis Campaign: Research Opportunities for Infection and Blood Purification Therapies.Crit Care Explor. 2021 Sep 7;3(9):e0511. doi: 10.1097/CCE.0000000000000511. eCollection 2021 Sep. Crit Care Explor. 2021. PMID: 34514420 Free PMC article. Review.
-
Circulating Factors in Trauma Plasma Activate Specific Human Immune Cell Subsets.Injury. 2020 Apr;51(4):819-829. doi: 10.1016/j.injury.2020.03.009. Epub 2020 Mar 4. Injury. 2020. PMID: 32171537 Free PMC article.
-
HCMV carriage in the elderly diminishes anti-viral functionality of the adaptive immune response resulting in virus replication at peripheral sites.Front Immunol. 2022 Dec 15;13:1083230. doi: 10.3389/fimmu.2022.1083230. eCollection 2022. Front Immunol. 2022. PMID: 36591233 Free PMC article.
References
-
- Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870–880. - PubMed
-
- Sinclair J, Sissons P. Latency and reactivation of human cytomegalovirus. J Gen Virol 2006; 87(Pt 7): 1763–1779. - PubMed
-
- Hodson EM, Jones CA, Webster AC, Strippoli GF, Barclay PG, Kable K et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365: 2105–2115. - PubMed
-
- Strippoli GF, Hodson EM, Jones C, Craig JC. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006; 81: 139–145. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials